[A21-166] Ozanimod (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V
Last updated 20.05.2022
Project no.:
A21-166
Commission:
Commission awarded on 14.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Adults with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional treatment or a biologic drug
- Patients who have had an inadequate response with, lost response to, or have intolerance or contraindications to conventional treatment: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or are intolerant to treatment with a biologic drug (TNFα antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 2.0 of the dossier assessment replaces version 1.0 published on 2022-03-15.
| Project no. | Title | Status |
|---|---|---|
| A20-59 | Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |